Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial entities : Amgen inc. save search
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Published: 2022-10-11 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.12%
H: 2.63%
C: 1.59%
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: 1.06%
H: 3.53%
C: 0.95%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 3.16%
H: 4.59%
C: 2.48%
bbp-398 lumakras fda designation lung pharma trial cancer fast track designation
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published: 2022-08-30 (Crawled : 21:00) - prnewswire.com
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: 0.12%
H: 0.16%
C: -0.31%
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 3.3%
H: 1.98%
C: 0.39%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 1.03%
H: 0.95%
C: -0.53%
lumakras lung topline trial cancer
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
Published: 2022-07-27 (Crawled : 11:00) - biospace.com/
IDYA | News | $39.85 2.13% 2.08% 1.3M
|
Health Technology
|
| O: 1.12%
H: 2.86%
C: 1.89%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.79%
H: 1.44%
C: 1.03%
collaboration trial
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 4.23%
H: 6.03%
C: 2.76%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.33%
H: 0.52%
C: -0.47%
lumakras trial 100 cancer pancreatic
Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published: 2021-09-28 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.12%
H: 1.77%
C: -0.99%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.16%
H: 0.04%
C: -0.51%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.09%
H: 0.93%
C: -0.26%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: -1.12%
H: 0.52%
C: -2.17%
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: -2.67%
H: 1.27%
C: -5.48%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.38%
H: 1.16%
C: -0.01%
clinical trials therapy car-t trials trial t-cell
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
Published: 2021-04-12 (Crawled : 20:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: -4.44%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.17%
H: 0.6%
C: 0.17%
lung cancer results cancer trial
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 1.06%
H: 0.92%
C: -3.19%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.89%
covid phase 2 trial brukinsa
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025
Published: 2021-03-10 (Crawled : 12:39) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 0.98%
H: 0.39%
C: -3.74%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 1.08%
H: 0.88%
C: -0.65%
phase 1 trial phase 3 phase 2
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Published: 2020-12-22 (Crawled : 08:07) - prnewswire.com
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.7%
H: 0.33%
C: -2.1%
phase 3 trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.